Komori
M&A and Subsidiary Changes4507Shionogi & Co.,Ltd.Pharmaceuticals

Completion of the acquisition of IntraBio

The acquisition to make IntraBio Inc. a wholly owned subsidiary, announced on 5 October 2026, was completed on 18 November 2026. Through the acquisition, the Shionogi group acquired the rare disease treatment AQNEURSA and expertise and development capabilities in rare diseases.

Worth reading
73In focus
Scored from 3 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

This transaction

Acquisition of IntraBio
Counterparty (target company)IntraBio Inc.
Disclosing companyShionogi & Co.,Ltd.
Subject of this transaction
Execution Date / Effective Date18 November 2026 (acquisition completed)
Target company

It is stated that the company has new expertise and capabilities in rare diseases and develops and provides AQNEURSA®, a treatment for neurological symptoms of Niemann-Pick disease type C (NPC) and ataxia associated with ataxia-telangiectasia (A-T), but the business activities of the target company itself are Not disclosed

Location Texas, USA
Impact on Business Performance

The impact on consolidated results for the fiscal year ending March 2027 is incorporated into the revised consolidated earnings forecasts announced on 29 October 2026

Procedures and assumptions
Management structure after acquisitionThe programs initiated by IntraBio will be continued, and the potential of AQNEURSA in other rare diseases will be considered going forward. The trade name, representative and employee arrangements are Not disclosed
This transaction
ItemDetails
Transaction nameAcquisition of IntraBio
Counterparty nameIntraBio Inc.
Name of the Subject CompanyIntraBio Inc.
Business Description of the Subject CompanyIt is stated that the company has new expertise and capabilities in rare diseases and develops and provides AQNEURSA®, a treatment for neurological symptoms of Niemann-Pick disease type C (NPC) and ataxia associated with ataxia-telangiectasia (A-T), but the business activities of the target company itself are Not disclosed
Location of the Subject CompanyTexas, USA
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending March 2027 is incorporated into the revised consolidated earnings forecasts announced on 29 October 2026
Execution Date / Effective Date18 November 2026 (acquisition completed)
Management structure after acquisitionThe programs initiated by IntraBio will be continued, and the potential of AQNEURSA in other rare diseases will be considered going forward. The trade name, representative and employee arrangements are Not disclosed
Items this document does not state (24)
Capital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand and strengthen its global efforts in rare diseases by adding AQNEURSA to its portfolio and acquiring expertise and capabilities in rare diseases.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Completion of the acquisition of IntraBio | Shionogi & Co.,Ltd. (4507) timely disclosure | Komori